Rhythm Closes Additional $8M in Series B Financing

Rhythm, a Boston, MA-based biotechnology company, has closed on an additional $8m in Series B financing.

Pfizer Venture Investments, the venture capital arm of Pfizer, has joined existing investors MPM Capital, New Enterprise Associates, Third Rock Ventures, and Ipsen, which all participated in a first closing of the Series B round earlier this year (read here).

Led by Bart Henderson, Co-Founder and President, Rhythm is developing the ghrelin peptide agonist, RM-131, for the treatment of diabetic gastroparesis and other GI functional disorders, and the MC4R peptide agonist, RM-493, for obesity and diabetes.

The company, which raised €40m in Series A in 2010 (read here), intends to use the capital to development its “small-peptide therapeutics” for metabolic diseases.



Join the discussion